Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan

European Journal of Haematology

Volumn 70, Issue 6, 2003, Pages 392-397

  Peng, Ching Tien ^a   Chow, Kuan Chih ^a   Chen, Jeon Hor ^a   Chiang, Yi Ping ^a   Lin, Tze Yi ^a   Tsai, Chang Hai ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cardiac; Cardiac function; Chelation; Deferiprone; Desferrioxamine; Iron averload; Left ventricular ejection fraction; Magnetic resonance imaging; Thalassemia

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE;

ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; IRON OVERLOAD; LIFE EXPECTANCY; LIVER BIOPSY; LIVER DISEASE; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TAIWAN;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PYRIDONES; STROKE VOLUME; TAIWAN;

EID: 0038472463     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00071.x     Document Type: Conference Paper

References (33)

1. KONTOGHIORGHES GJ, PATTICHI K, HADJIGAVRIEL M, KOLNAGOU A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-223.
2. OLIVIERI NF, BRITTENHAM GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
3. PENG CT, TSAI CH, WANG JH, CHIU CF, CHOW KC. Bacterial infection in patients with transfusion-dependent beta-thalassemia in central Taiwan. Acta Paediatr Taiwan 2000;41:318-321.
4. KONTOGHIORGHES GJ, ALDOURI MA, HOFFBRAND AV, BARR J, WONKE B, KOUROUCLARIS T, SHEPPARD L. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 1987;295:1509-1512.
5. KONTOGHIORGHES GJ, ALDOURI MA, SHEPPARD L, HOFFBRAND AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;I:1294-1295.
6. PORTER JB, HUEHNS ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989;2:454-459.
7. MODELL B, KHAN M, DARLISON M. Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
8. JENSEN PD, BAGGER JP, JENSEN FT, BAANDRUP U, CHRISTENSEN T, ELLEGAARD J. Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies. Eur J Haematol 1993;51:199-205.
9. BONKOVSKY HL, RUBIN RB, CABLE EL, DAVIDOFF A, RIJCKEN TH. STARK DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999;212:227-234.
10. ANDERSON LJ, HOLDEN S, DAVIS B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
11. ANDERSON LJ, WONKE B, PRESCOTT E, HOLDEN S, WALKER JM, PENNELL DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
12. VREUGDENHIL G, SWAAK AJ, KONTOGHIORGHES GJ, van EIJK HG. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet 1989;2:1398-1399.
13. TAHER A, SHEIKH-TAHA M, KOUSSA S, INATI A, NEEMAN R, MOURAD F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001;67:30-34.
14. FREEMAN AP, GILES RW, BERDOUKAS VA, TALLEY PA, MURRAY IP. Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin Lab Haematol 1989;11:299-307.
15. LIVINGSTON DM, WACKER WE. Trace metal methods for nutritional studies. Am J Clin Nutr 1971;24:1082-1085.
16. PERLS M. Eisenoxyd in gewissen pigmentosen. Virchows Arch Pathol Anat 1867;39:42-45.
17. OLIVIERI NF, NATHAN DG, MACMILLAN JH, WAYNE AS, LIU PP, MCGEE A, MARTIN M, KOREN G, COHEN AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578.
18. KONTOGHIORGHES GJ, BARTLETT AN, HOFFBRAND AV, GODDARD JG, SHEPPARD L, BARR J, NORTEY P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300.
19. TONDURY P, KONTOGHIORGHES GJ, RIDOLFI-LUTHY A, HIRT A, HOFFBRAND AV, LOTTENBACH AM, SONDEREGGER T, WAGNER HP. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for iron chelation in patients with beta-thalassemia major. Br J Haematol 1990;76:550-553.
20. AGARWAL MB, GUPTE SS, VISWANATHAN C, RAMANATHAN J, DESAI N, PUNIYANI RR, CHHABLANI AT. Long-term assessment of efficacy and safety of L1 an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 1992;82:460-466.
21. AL-REFAIE FN, WONKE B, HOFFBRAND AV, WICKEN DG, NORTEY P, KONTOGHIORGHES GJ. Efficacy and possible adverse effects of the oral chelator L1 in thalassemia major. Blood 1992;80:593-599.
22. OLIVIERI NF, KOREN G, MATSUI D, LIU PP, BLENDIS L, CAMERON R, MCCLELLAND RA, TEMPLETON DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;15:2741-2748.
23. COLLINS AF, FASSOS FF, STOBIE S, LEWIS N, SHAW D, FRY M, TEMPLETON DM, MCCLELLAND RA, KOREN G, OLIVIERI NF. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-2333.
24. AL-REFAIE FN, HERSHKO C, HOFFBRAND AV, KOSARYAN M, OLIVIERI NF, TONDURY P, WONKE B. Results of long term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators. Br J Haematol 1995;91:224-229.
25. OLIVIERI NF, BRITTENHAM GM, MATSUI D, BERKOVITCH M, BLENDIS LM, CAMERON RG, MCCLELLAND RA, LIU PP, TEMPLETON DM, KOREN G. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918-922.
26. OLIVIERI NF, BRITTENHAM GM, MCLAREN CE, TEMPLETON DM, CAMERON RG, MCCLELLAND RA, BURT AD, FLEMING KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 1998;339:417-423.
27. WONKE B, WRIGHT C, HOFFBRAND AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
28. PORTER JB, HOYES KP, ABEYSINGHE RD, BROOKS PN, HUEHNS ER, HIDER RC. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991;78:2727-2734.
29. JOHNSTON DL, RICE L, VICK GW III, HEDRICK TD, ROKEY R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989;87:40-47.
30. MAVROGENI SI, MARIS T, GOULIAMOS A, VLAHOS L, KREMASTINOS DT. Myocardial iron deposition in betathalassemia studied by magnetic resonance imaging. Int J Card Imaging 1998;14:117-122.
31. OOI GC, CHEN FE, CHAN KN, TSANG KW, WONG YH, LIANG R, CHAN V, NGAN H. Qualitative and quantitative magnetic resonance imaging in haemoglobin H disease: screening for iron overload. Clin Radiol 1999;54:98-102.
32. TELFER PT, PRESTCOTT E, HOLDEN S, WALKER M, HOFFBRAND AV, WONKE B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-977.
33. BRITTENHAM GM, COHEN AR, MCLAREN CE, MARTIN MB, GRIFFITH PM, NIENHUIS AW, YOUNG NS, ALLEN CJ, FARRELL DE, HARRIS JW. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85.